Reneuron Group (RENE)


Latest News

Block Listing Review and TVR

RNS Number: 3082G ReNeuron Group plc 01 March 2018 1 March 2018 AIM: RENE ReNeuron Group plc Block Listing Review and Total Voting Rights ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Co...

Block Listing Application

RNS Number: 0611F ReNeuron Group plc 16 February 2018 16 February 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Block Listing Application ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that an application has been made to the London Stock Exchange plc ...

Positive pre-clinical data in nerve injury

RNS Number: 7283E ReNeuron Group plc 13 February 2018 13 February 2018 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Positive pre-clinical data in nerve injury Positive pre-clinical data published using ReNeuron's CTX cells in artificial nerve tissue generated as part of a grant-funded collaboration ReNeuron Group plc (AIM: RENE), a UK...

ReNeuron presents treatment trial results

ReNeuron Group said that positive long-term clinical trial data for a stroke disability treatment was accepted for a podium...

All News

01-03-18Block Listing Review and TVRRNS
16-02-18Block Listing ApplicationRNS
13-02-18Positive pre-clinical data in nerve injuryRNS
26-01-18ReNeuron presents treatment trial resultsStockMarketWire
26-01-18Phase II stroke data presented at AHA conferenceRNS
23-01-18ReNeuron shareholders approval capital re-organisationStockMarketWire
11-01-18Further re Share Capital ReorganisationRNS
05-01-18ReNeuron Group plans share reductionStockMarketWire
05-01-18Proposed Share Capital ReorganisationRNS
14-12-17ReNeuron losses widenStockMarketWire
14-12-17Interim resultsRNS
14-12-17Stroke clinical trial regulatory approval in USRNS
08-12-17ReNeuron Group opens Boston officeStockMarketWire
08-12-17ReNeuron opens US officeRNS
13-11-17Notification of Interim ResultsRNS
08-11-17ReNeuron clinical trial enters next phaseStockMarketWire
08-11-17Retinal disease clinical trial moves into Phase IIRNS
31-10-17ReNeuron reports positive trial dataStockMarketWire
31-10-17Positive stroke clinical data & regulatory updateRNS
27-10-17ReNeuron wins Welsh grantStockMarketWire
27-10-17Wins further UK grantRNS
11-10-17PDMR Interest in Shares and Share OptionsRNS
09-10-17Presentation of positive pre-clinical dataRNS
12-09-17Directors' Interest in Shares and Share OptionsRNS
06-09-17Result of AGMRNS
06-09-17AGM Trading UpdateRNS
01-09-17Non-executive Director AppointmentRNS
01-09-17Block Listing Review and TVRRNS
07-08-17Neil Woodford 'very confident' he can deliver 10%-plus yearly returnsMoney Observer
07-08-17Posting of Annual Report and Notice of AGMRNS
04-08-17Second Price Monitoring ExtnRNS
04-08-17Price Monitoring ExtensionRNS
25-07-17Appointment of joint brokerRNS
19-07-17Board changeRNS
29-06-17ReNeuron widens FY pretax lossStockMarketWire
29-06-17Preliminary ResultsRNS
19-06-17ReNeuron says FDA okays cryopreserved hRPC formulationStockMarketWire
19-06-17FDA approves cryopreserved hRPC formulationRNS
08-06-17Notification of Preliminary ResultsRNS
05-06-17ReNeuron gets favourable feedback from US FDAStockMarketWire

RSS feeds

  • Editorial news feed for LSE:RENE Editorial
  • Regulatory news feed for LSE:RENE Regulatory